FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $32,620 | -82.2% | 15,387 | -60.1% | 0.00% | -85.7% |
| Q2 2023 | $183,641 | -88.0% | 38,580 | -74.5% | 0.01% | -92.4% |
| Q4 2022 | $1,525,124 | +50.9% | 151,152 | +235.1% | 0.09% | +46.0% |
| Q3 2022 | $1,011,000 | -4.4% | 45,113 | +65.5% | 0.06% | +53.7% |
| Q1 2022 | $1,057,000 | -12.9% | 27,252 | +33.1% | 0.04% | -40.6% |
| Q3 2021 | $1,214,000 | -9.6% | 20,482 | +32.4% | 0.07% | -19.8% |
| Q2 2021 | $1,343,000 | +42.6% | 15,474 | +35.4% | 0.09% | +83.0% |
| Q1 2021 | $942,000 | +240.1% | 11,430 | +64.7% | 0.05% | +261.5% |
| Q3 2020 | $277,000 | -21.8% | 6,939 | -32.8% | 0.01% | -27.8% |
| Q2 2020 | $354,000 | +22.9% | 10,322 | -44.3% | 0.02% | +20.0% |
| Q3 2019 | $288,000 | +28.0% | 18,548 | +67.1% | 0.02% | +25.0% |
| Q2 2019 | $225,000 | – | 11,100 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $34,095 | 9.92% |
| Redmile Group, LLC | 12,957,222 | $130,738,370 | 5.35% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $10,465,913 | 2.67% |
| Casdin Capital, LLC | 2,050,000 | $20,684,500 | 1.60% |
| DAFNA Capital Management LLC | 550,940 | $5,558,985 | 1.57% |
| Artal Group S.A. | 2,600,000 | $26,234 | 1.46% |
| Monaco Asset Management SAM | 250,000 | $2,522,500 | 0.76% |
| Parametrica Management Ltd | 32,254 | $325,443 | 0.67% |
| Boxer Capital, LLC | 1,250,000 | $12,612,500 | 0.66% |
| Bellevue Group AG | 4,861,279 | $49,050,305 | 0.65% |